logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Medical Aesthetics Market, By Type (Facial Aesthetic, Body Contorting Aesthetic, Cosmetic Implants, Skin Aesthetic Devices, Hair Removal Devices, Tattoo Removal Devices), By End Use (Hospital, Clinics and Medical Spas, Beauty Centres, and Homecare settings) opportunities and forecast 2020-2027

  • DLR2201
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

The term medical aesthetics denotes the medicine that is a largely extensive term used for specialties that focuses on improvement of cosmetic appearance of the body by the process of treatment of the skin laxity, moles, scars, wrinkles, liver spots, excess fat, cellulite, unwanted hair, skin discoloration and spider veins,. Generally, the aesthetic medicine includes the reconstructive surgery, plastic surgery, oral and maxillofacial surgery and dermatology.

The growing acceptance of minimally invasive and non-invasive aesthetic processes, increasing adoption among the geriatric individuals, growing public awareness about the cosmetic procedures, availability of technologically advanced and user-friendly products, along with the increasing demand for these treatments among women and men are the major factors driving the growth of the market. However, market growth is restricted to a certain level by the factors such as the complications and clinical risks associated with the medical aesthetic procedures and increasing adoption and availability of alternative cosmetic and beauty products.

Segment Overview

The facial aesthetic products are expected to hold the major share of the market in 2018. The large share is attributed to the rising patient demand for facial treatments, growing disposable income and spending capabilities, and rising geriatric population through the globe.
Based on end user, the market is segmented into beauty centers; clinics, hospitals, and medical spas; and home care. The clinics, hospitals, and medical spas segment is projected to account for largest share of the global market in 2018. The segment is also likely to be fastest-growing end-user segment over the forecast period, due to the growing number of clinics and medical spas and high availability of infrastructural and financial resources with hospitals, with trained staff, technologically advanced devices, and skilled professionals to perform the aesthetic procedures.

Regional Overview

Geographically, the market is divided into North America, Asia Pacific, Europe, and Latin America and Middle East and Africa. North America is projected to account for largest share of the global market in 2018. The large share can be attributed to the rising procedural volume for these procedures and high adoption rate of new technologies in this region.
The APAC market is projected to register the highest growth during the forecast period. The major factors leading to the growth of the APAC market include rising consumer interest and awareness in aesthetic procedures, aggressive marketing by the U.S. and European companies, and also the rising medical tourism in the region.

Competitor overview

In 2017, Allergan, Galderma, Cynosure, Syneron Candela, Mentor (a subsidiary of Johnson & Johnson) lead the global medical aesthetic market. Allergan, plc. Is among the leading major companies in the market. The company has a wide product portfolio and emphases on continuous innovation and the new product development to sustain the leadership position in the market. In the last few years, the company has enhanced its market share by introducing new products and new approvals for various aesthetic products.

For instance, the company received the FDA approval for Coolsculpting treatment, NATRELLE INSPIRA, BOTOX Cosmetic, JUVÉDERM VOLLURE XC gel filler, in the last three years. The company launched new products, including Juvéderm Volite and JUVÉDERM VOLBELLA XC during the same period. A strong emphasis on this organic growth strategy enables the company to increase its product portfolio and cater to growing needs of the patients and surgeons.

Key Players
  1. Allergan
  2. Galderma
  3. Cynosure
  4. Syneron Candela
  5. Mentor (Johnson & Johnson)
  6. Alma Lasers, Ltd.
  7. Anika Therapeutics
  8. Cutera, Inc.
  9. El.En. S.p.A.
  10. Fotona d.o.o.
  11. Nestlé S.A.
  12. Merz Pharma GmbH & Co. KGaA
  13. Medytox, Inc.
  14. Sientra, Inc.
  15. Sinclair Pharma PLC

Market Segmentation

By Product
  • Facial Aesthetic Products
  • Body Contouring Devices
  • Cosmetic Implants
  • Physician-Dispensed Cosmeceuticals and Skin Lighteners
  • Skin Aesthetic Devices
  • Physician-Dispensed Eyelash Products
  • Hair Removal Devices
  • Tattoo Removal Devices
  • Thread Lift Products
  • Nail Treatment Laser Devices
By End Use
  • Clinics, Hospitals, and Medical S.P.A.s
  • Beauty Centres
  • Home Care Settings
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 EXECUTIVE SUMMARY 15

  • 1.1 MARKET SYNOPSIS 15

2 MARKET INTRODUCTION 17

  • 2.1 DEFINITION 17
  • 2.2 SCOPE OF THE STUDY 17
  • 2.3 RESEARCH OBJECTIVE 17
  • 2.4 MARKET STRUCTURE 18
  • 2.5 ASSUMPTIONS & LIMITATIONS 18

3 RESEARCH METHODOLOGY 19

    4 MARKET DYNAMICS 28

    • 4.1 OVERVIEW 28
    • 4.2 DRIVERS 29
      • 4.2.1 HIGH DEMAND FOR LIPOSUCTION, HAIR TRANSPLANTATION, AND THE RISING OBESE AND GERIATRIC POPULATION 29
      • 4.2.2 GROWING EXPENDITURE ON COSMETIC SURGERIES 29
      • 4.2.3 PREVALENCE OF SKIN DISEASES 30
      • 4.2.4 TECHNOLOGICAL ADVANCEMENTS IN THE AESTHETIC INDUSTRY 30
      • 4.2.5 INCREASING ACCEPTANCE OF FACIAL AESTHETICS 30
    • 4.3 RESTRAINTS 31
      • 4.3.1 HIGH PROCEDURAL COSTS 31
      • 4.3.2 LACK OF TRAINING FOR AESTHETIC PROCEDURES 31
      • 4.3.3 SIDE-EFFECTS ASSOCIATED WITH AESTHETICS PROCEDURES 32
    • 4.4 OPPORTUNITIES 33
      • 4.4.1 RISING DEMAND FOR MINIMALLY INVASIVE PROCEDURES 33

    5 MARKET FACTOR ANALYSIS 34

    • 5.1 PORTER’S FIVE FORCES MODEL 34
      • 5.1.1 BARGAINING POWER OF SUPPLIERS 35
      • 5.1.2 BARGAINING POWER OF BUYERS 35
      • 5.1.3 THREAT OF NEW ENTRANTS 35
      • 5.1.4 THREAT OF SUBSTITUTES 35
      • 5.1.5 INTENSITY OF RIVALRY 35
    • 5.2 VALUE CHAIN ANALYSIS 36
      • 5.2.1 RESEARCH & DEVELOPMENT 37
      • 5.2.2 MANUFACTURING 37
      • 5.2.3 DISTRIBUTION 37
      • 5.2.4 MARKETING & SALES 37
      • 5.2.5 POST-SALES MONITORING 37
    • 5.3 INVESTMENT OPPORTUNITIES 38
    • 5.4 PRICE ANALYSIS 38

    6 GLOBAL MEDICAL AESTHETICS MARKET, BY PRODUCT 39

    • 6.1 OVERVIEW 39
    • 6.2 FACIAL AESTHETIC 41
      • 6.2.1 BOTULINUM TOXIN 41
      • 6.2.2 DERMAL FILLERS 42
      • 6.2.3 MICRODERMABRASION DEVICES 42
      • 6.2.4 OTHERS 43
    • 6.3 BODY CONTOURING DEVICES 43
      • 6.3.1 NONSURGICAL FAT REDUCTION DEVICES 44
      • 6.3.2 CELLULITE REDUCTION DEVICES 45
      • 6.3.3 LIPOSUCTION DEVICES 45
    • 6.4 COSMETIC IMPLANTS 46
      • 6.4.1 BREAST IMPLANTS 47
      • 6.4.2 FACIAL IMPLANTS 47
      • 6.4.3 OTHERS 47
    • 6.5 HAIR REMOVAL DEVICES 48
    • 6.6 SKIN AESTHETIC DEVICES 48
      • 6.6.1 LASER SKIN RESURFACING DEVICES 49
      • 6.6.2 NONSURGICAL SKIN TIGHTENING DEVICES 50
      • 6.6.3 MICRO-NEEDLING PRODUCTS 50
      • 6.6.4 LIGHT THERAPY DEVICE 51
    • 6.7 TATTOO REMOVAL DEVICES 51
    • 6.8 OTHERS 52

    7 GLOBAL MEDICAL AESTHETICS MARKET, BY END USER 53

    • 7.1 OVERVIEW 53
    • 7.2 HOSPITALS & CLINICS 54
    • 7.3 DERMATOLOGY & COSMETIC CENTERS 54
    • 7.4 OTHERS 55

    8 GLOBAL MEDICAL AESTHETICS MARKET, BY REGION 56

    • 8.1 OVERVIEW 56
    • 8.2 AMERICAS 58
      • 8.2.1 NORTH AMERICA 60
        • 8.2.1.1 US 63
        • 8.2.1.2 CANADA 66
      • 8.2.2 LATIN AMERICA 68
    • 8.3 EUROPE 71
      • 8.3.1 GERMANY 74
      • 8.3.2 FRANCE 77
      • 8.3.3 UK 79
      • 8.3.4 ITALY 82
      • 8.3.5 SPAIN 84
      • 8.3.6 IRELAND 87
      • 8.3.7 REST OF EUROPE 89
    • 8.4 ASIA-PACIFIC 92
      • 8.4.1 CHINA 95
      • 8.4.2 JAPAN 98
      • 8.4.3 SOUTH KOREA 100
      • 8.4.4 INDIA 103
      • 8.4.5 AUSTRALIA 105
      • 8.4.6 REST OF ASIA-PACIFIC 108
    • 8.5 MIDDLE EAST & AFRICA 111
      • 8.5.1 MIDDLE EAST 114
      • 8.5.2 AFRICA 116

    9 COMPETITIVE LANDSCAPE 119

    • 9.1 INTRODUCTION 119
    • 9.2 COMPETITIVE BENCHMARKING 120
    • 9.3 KEY DEVELOPMENTS 121

    10 COMPANY PROFILES 123

    • 10.1 ALLERGAN 123
      • 10.1.1 COMPANY OVERVIEW 123
      • 10.1.2 FINANCIAL OVERVIEW 123
      • 10.1.3 PRODUCTS/SERVICES OFFERED 124
      • 10.1.4 ALLERGAN: KEY DEVELOPMENTS 124
      • 10.1.5 SWOT ANALYSIS 125
      • 10.1.6 KEY STRATEGIES 125
    • 10.2 MERZ PHARMA GMBH & CO. KGAA 126
      • 10.2.1 COMPANY OVERVIEW 126
      • 10.2.2 FINANCIAL OVERVIEW 126
      • 10.2.3 PRODUCTS/SERVICES OFFERED 127
      • 10.2.4 KEY DEVELOPMENTS 127
      • 10.2.5 SWOT ANALYSIS 128
      • 10.2.6 KEY STRATEGIES 128
    • 10.3 LUMENIS 129
      • 10.3.1 COMPANY OVERVIEW 129
      • 10.3.2 FINANCIAL OVERVIEW 129
      • 10.3.3 PRODUCTS/SERVICES OFFERED 129
      • 10.3.4 KEY DEVELOPMENTS 130
      • 10.3.5 SWOT ANALYSIS 130
      • 10.3.6 KEY STRATEGIES 130
    • 10.4 HOLOGIC INC. 131
      • 10.4.1 COMPANY OVERVIEW 131
      • 10.4.2 FINANCIAL OVERVIEW 131
      • 10.4.3 PRODUCTS/SERVICES OFFERED 132
      • 10.4.4 KEY DEVELOPMENTS 132
      • 10.4.5 SWOT ANALYSIS 133
      • 10.4.6 KEY STRATEGIES 133
    • 10.5 GALDERMA SA 134
      • 10.5.1 COMPANY OVERVIEW 134
      • 10.5.2 FINANCIAL OVERVIEW 134
      • 10.5.3 PRODUCTS/SERVICES OFFERED 135
      • 10.5.4 KEY DEVELOPMENTS 135
      • 10.5.5 SWOT ANALYSIS 135
      • 10.5.6 KEY STRATEGIES 136
    • 10.6 BAUSCH HEALTH (VALEANT PHARMACEUTICALS) 137
      • 10.6.1 COMPANY OVERVIEW 137
      • 10.6.2 FINANCIAL OVERVIEW 137
      • 10.6.3 PRODUCTS/SERVICES OFFERED 138
      • 10.6.4 KEY DEVELOPMENTS 138
      • 10.6.5 SWOT ANALYSIS 138
      • 10.6.6 KEY STRATEGIES 139
    • 10.7 ANIKA THERAPEUTICS INC. 140
      • 10.7.1 COMPANY OVERVIEW 140
      • 10.7.2 FINANCIAL OVERVIEW 140
      • 10.7.3 PRODUCTS/SERVICES OFFERED 141
      • 10.7.4 KEY DEVELOPMENTS 141
      • 10.7.5 SWOT ANALYSIS 141
      • 10.7.6 KEY STRATEGIES 141
    • 10.8 CUTERA 142
      • 10.8.1 COMPANY OVERVIEW 142
      • 10.8.2 FINANCIAL OVERVIEW 142
      • 10.8.3 PRODUCTS/SERVICES OFFERED 143
      • 10.8.4 KEY DEVELOPMENTS 143
      • 10.8.5 SWOT ANALYSIS 144
      • 10.8.6 KEY STRATEGIES 144
    • 10.9 ALMA LASERS 145
      • 10.9.1 COMPANY OVERVIEW 145
      • 10.9.2 FINANCIAL OVERVIEW 145
      • 10.9.3 PRODUCTS/SERVICES OFFERED 146
      • 10.9.4 KEY DEVELOPMENTS 146
      • 10.9.5 SWOT ANALYSIS 147
      • 10.9.6 KEY STRATEGIES 147
    • 10.10 SYNERON MEDICAL LTD 148
      • 10.10.1 COMPANY OVERVIEW 148
      • 10.10.2 FINANCIAL OVERVIEW 148
      • 10.10.3 PRODUCTS/SERVICES OFFERED 148
      • 10.10.4 KEY DEVELOPMENTS 148
      • 10.10.5 SWOT ANALYSIS 149
      • 10.10.6 KEY STRATEGIES 149

    11 APPENDIX 150

    • 11.1 REFERENCES 150
    • 11.2 RELATED REPORTS 151

    Report You Might be Interested